Emily Estrada

Final safety and patient-reported outcome data from the phase 3 TROPION-Breast01 trial showed that datopotamab deruxtecan was associated with fewer

Patient-reported outcome data from the phase 3 DeLLphi-304 trial showed that tarlatamab improved symptom burden and delayed deterioration in multiple

A planned patient-reported outcome analysis from the NRG-LU005 trial showed that adding atezolizumab to chemoradiation did not significantly reduce

A multidisciplinary Delphi consensus established recommendations for staging and surveillance imaging in localized cutaneous squamous cell

Results from a real-world study found that durable disease control was frequently achieved after limited PD-1 inhibitor exposure in patients with

Based on results from the phase 3 SURPASS ET trial, the US Food and Drug Administration (FDA) has approved ropeginterferon alfa-2b (BESREMi; PharmEssentia) for

Topline results from the phase 2a NEO100-01 trial showed that intranasal NEO100 achieved a 48.9% 6-month progression-free survival rate in patients with recurrent IDH1-mutant high-grade glioma, significantly exceeding the prespecified 20%...

The FDA has approved rusfertide for the treatment of erythrocytosis in adult patients with polycythemia vera after results from the phase 3 VERIFY trial showed showed improved hematocrit control, reduced phlebotomy requirements, and improved...

Results from the real-world DeNi trial demonstrated durable disease control, tumor responses, and pain improvement with nirogacestat in patients

Based on results from the phase 3 SERENA-6 trial, the US Food and Drug Administration (FDA) granted accelerated approval to camizestrant (Etcamah; AstraZeneca) in